Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study. by Berry, Brendan et al.
1 
21st February 2020 – Accepted Manuscript – British Journal of Urology International 
 
Title: Comparison of complications after transrectal and transperineal prostate 
biopsy: a national population-based study. 
 
Authors: Brendan Berry, BBa,b,*; Matthew G. Parry, MGBa,b,*; Arunan Sujenthiran, 
ASb; Julie Nossiter, JNb; Thomas E. Cowling, TECa,b; Ajay Aggarwal, AAc,d,; Paul 
Cathcart, PCe; Heather Payne, HPf; Jan van der Meulen, JvdMa,b+; W. Clarke, 
NWCg+ 
a. Department of Health Services Research and Policy, London School of Hygiene and 
Tropical Medicine, London UK 
b. Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK 
c. Department of Radiotherapy, Guy’s and St Thomas’ NHS Foundation Trust, London, UK 
d. Department of Cancer Epidemiology, Population, and Global Health, King’s College 
London, London UK 
e. Department of Urology, Guy’s and St Thomas’ NHS Foundation Trust, London UK 
f. Department of Oncology, University College London Hospitals NHS Foundation Trust, 
London, UK 
g. Department of Urology, The Christie and Salford Royal Hospitals Manchester NHS 
Foundation Trust, Manchester, UK  
 
Corresponding Author: Brendan Berry (bberry@rcseng.ac.uk) 
Clinical Effectiveness Unit, Royal College of Surgeons of England, 35-43 Lincoln’s 
Inn Fields, London WC2A 3PE, UK 
* Joint first authors          + Joint senior authors 
Keywords: Prostate biopsy; Prostate cancer, Transrectal; Transperineal; Sepsis; 
Urinary retention; Haematuria; Length of hospital stay 
Word count of text: 2479  Word count of abstract: 246 
2 




To assess the complications of transrectal (TR) compared to transperineal prostate 
(TP) biopsies. 
 
Patients and Methods: 
Men diagnosed with prostate cancer between 1st April 2014 and 2017 in England 
were identified by the National Prostate Cancer Audit. Administrative hospital data 
were then used to categorise the type of prostate biopsy and subsequent 
complications requiring hospital admission. 
 
Administrative hospital data were used to identify patients staying overnight 
immediately after biopsy and those readmitted separately for hospital admissions 
because of sepsis, urinary retention or haematuria. Procedure related mortality and 
total length of hospital stay within 30 days was also recorded. Generalised linear 
models were used to calculate adjusted risk differences (aRD). 
 
Results: 
73,630 men undergoing prostate biopsy were identified. Those having TP biopsy 
(n=13,723) were more likely to have an overnight hospital stay (12.3% vs 2.4%; aRD 
9.7%: 95% CI 7.1% to 12.3%), were less likely to be readmitted because of sepsis 
(1.0% vs 1.4%; aRD -0.4%: CI -0.6% to -0.2%), and were more likely to be 
readmitted with urinary retention (1.9% vs 1.0%; aRD 1.1%: CI 0.7% to 1.4%) than 
those undergoing a TR biopsy (n=59,907). There were no significant differences in 
the risk of haematuria or mortality.  
3 




TP biopsy has a lower risk of readmission for sepsis but a higher risk of readmission 
for urinary retention than TR biopsy. Use of the TP route would prevent one 





Most men diagnosed with prostate cancer have a prostate biopsy (1). The transrectal 
(TR) route is currently the most common technique in most countries but 
transperineal biopsy (TP) is used increasingly (1). 
 
TP biopsies are reported to have a lower risk of sepsis than TR biopsies but the 
most recent systematic review reported only seven small studies comparing the 
safety of both routes directly (2). This review, which included a total of 1618 patients, 
is too small to allow precise estimates of the difference in the risk of sepsis, urinary 
retention and haematuria. It is therefore unclear whether the risk of complications is 
significantly different between TP to TR biopsies (3-5), something which is reflected 
in the uncertainty of national and international guidelines  
 
We compared the risk of sepsis, urinary retention and haemorrhage after TR and TP 
prostate biopsies in all men included in the National Prostate Cancer Audit (1) who 
were diagnosed with prostate cancer between 1st April 2014 and 31st March 2017 in 
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the English National Health Service (NHS), using cancer registry and administrative 
hospital data linked at patient level. 
 
 
Patients and Methods 
Data sources and patient population 
All patients newly diagnosed with prostate cancer between 1st April 2014 and 31st 
March 2017 and included in the National Prostate Cancer Audit were identified from 
the English cancer registry using the ICD 10 diagnosis code C61 and the date of 
cancer diagnosis (6).  
 
The data set was linked at patient-level to Hospital Episode Statistics (HES), which 
also included mortality data derived from the Office for National Statistics. HES is an 
administrative database of all hospital outpatient appointments and inpatient 
admissions in England. 
 
OPCS-4 procedure codes were used to identify men undergoing a TR (M70.3) 
and/or a TP biopsy (M70.2) (6). To account for the time interval between patient 
biopsy and date of diagnosis, all biopsies carried out from 1st January 2014 were 
identified to ensure biopsy data was available for all patients who received a cancer 
diagnosis from the 1st April 2014. For each patient, only the biopsy with a date 
closest to the date of diagnosis was taken to ensure that only a single biopsy session 
per patient was included. 
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118,526 men were identified with a prostate cancer diagnosis date between 1st April 
2014 and 31st March 2017 (Fig 1). Of these, 75,464 (63.7%) had a prostate biopsy 
identified in the HES database. 1008 men were excluded because they had their 
biopsy at a private hospital, 11 because the hospital where they had their biopsy was 
unknown and 815 men because the biopsy route was not documented. Overall, data 
from 73,630 men was available for analysis. 
 
Outcome variables 
Readmissions for sepsis, urinary retention or haematuria were identified using the 
ICD-10 and OPCS-4 codes as described elsewhere (7) (Appendix). Consequently, 
complications were only identified if they were severe enough to require a hospital 
admission,  which aligns with the Clavien-Dindo classification of a severe surgical 
complication (grade 3)(8). Previous studies of prostate biopsy complications have 
also used these outcomes to measure complications following this procedure. (2, 7, 
9, 10). 
 
Length of hospital stay following readmission within 30 days after biopsy was 
measured as a continuous outcome variable. HES records only report admission and 
discharge dates and therefore length of hospital stay was reported in days. For all 
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Patient characteristics 
The HES database was used to identify patient age, comorbidities, socioeconomic 
deprivation and ethnicity. The cancer registry was used to identify patient ethnicity in 
instances where HES records were incomplete. 
 
The Royal College of Surgeons (RCS) Charlson score was used to identify co-
morbid conditions captured in the HES record within one year prior to each patient’s 
prostate biopsy (11). Socioeconomic deprivation status was determined for patients 
from the English 2012 Index of Multiple Deprivation (IMD) based on their area of 
residence and divided according to quintiles of the national distribution (12). For 
ethnicity, men were categorised into four groups (white, asian, black and other). 
 
Statistical analysis  
Generalised linear models were used to estimate the adjusted risk differences 
between men who had a TR and TP biopsy. These models assumed a binomial 
distribution for the outcomes and used an identity link function. Multivariable linear 
regression was used to estimate the adjusted difference in the mean length of 
hospital stay following readmission within 30 days of biopsy. 
 
Analyses were adjusted for the year of biopsy, patient age, ethnicity, comorbidity, 
and socioeconomic deprivation. It also took into account that patients were clustered 
within hospitals (13). Missing values for ethnicity (n=4987, 6.7%) were imputed using 
multiple imputation by chained equations. 20 data sets were created and Rubin’s 
rules were used to combine estimates. Wald tests were used to calculate p values. 
The level for statistical significance was set at 0.05. 
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Of the 73,630 men included in the analysis, 59,907 (81.4%) underwent a TR biopsy 
and 13,723 (18.6%) a TP biopsy. Men undergoing a TP biopsy tended to have their 
biopsy more recently (51.4% vs 42.4% in the two most recent years of the inclusion 
period), were younger on average (62.9% vs 51. 5% younger than 70) and were 
more likely to have at least one co-morbid condition (28.3% vs 22.0%) than men 
undergoing TR biopsy (Table 1). 
 
TP biopsy patients were more likely to have an overnight stay immediately following 
the biopsy than those having TR biopsy (12.3% vs 2.4%; adjusted risk difference 
9.7%; 95% CI 7.1% to 12.3%) (Table 2). 
 
Men who had a TP biopsy were less likely to be readmitted because of sepsis (1.0% 
vs 1.4%; adjusted risk difference -0.4%; 95% CI -0.6% to -0.2%) but were more likely 
to be readmitted because of urinary retention (1.9% vs 1.0%; adjusted risk difference 
1.1%; 95% CI 0.7% to 1.4%) (Table 2). 155 of the 59,907 men who underwent a TR 
(0.2%) and 38 of the 13,723 who  underwent a TP biopsy (0.3%) had both sepsis 
and urinary retention.  
 
We found that the mean length of hospital stay after a readmission due to sepsis 
was shorter in those who had a TP biopsy than in those who had a TR biopsy (5.1 vs 
6.5 days; adjusted mean difference -1.1 days; 95% CI -1.8 to -0.4). The mean length 
of hospital stay after readmissions for urinary retention was also shorter than for TP 
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biopsy (2.6 vs 3.9 days; adjusted mean difference -1.3 days; 95% CI -2.0 to -0.7). No 
statistically significant difference was seen in length of stay for readmissions due to 






This is the largest study comparing the risk of complications following TP and TR 
prostate biopsies to date. Our results indicate that patients who underwent a TP 
biopsy between 1st April 2014 to 31st March 2017 were less likely to be readmitted to 
hospital because of sepsis but were more likely to be readmitted because of urinary 
retention than patients who had a TR biopsy. 
 
Comparison with other studies 
Two systematic reviews have recently compared complications after TR and TP 
biopsies. One review, published in 2017, found that four studies, including 971 
patients, reported on sepsis, four studies, including 710 patients, reported on urinary 
retention, and six studies, including 1327 patients, reported on haematuria. (9). This 
review concluded that there were no statistically significant differences in the risk of 
these complications after TR or TP biopsy. 
 
Another review, published in 2019, summarised seven studies, including 1618 
patients (2). This review found that sepsis was less likely after a TP biopsy but it did 
not find significant differences for urinary retention or haematuria. This systematic 
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review failed to include four studies that were previously included in the systematic 
review published in 2017 (9). The range of methods used to assess complication 
rates in the studies that were included in these reviews and the overall low statistical 
power are likely to explain the differences with the results reported in our study. 
 
One population-based study, conducted in New York State, comparing TR versus TP 
biopsy complications, was not included in the two systematic reviews mentioned 
above (10). This study included 9893 men and reported that sepsis was more 
common after a TR biopsy than after a TP biopsy (adjusted odds ratio 3.48; 95 CI 
1.27-9.54; P=0.02). It did not find statistically significant differences for urinary 
retention and haematuria. However, only 421 men (4.3% of the total study 
population) had a TP biopsy. This study was therefore inadequately powered to 
detect a meaningful difference in urinary retention rates. 
 
Clinical interpretation 
Our study highlights the dilemma in choosing between TR or TP biopsy as a means 
of reducing or avoiding biopsy-related complications. There is clearly a trade-off 
between the risk of sepsis and acute urinary retention. In this context, it is also 
important to note that the average length of stay due to sepsis or urinary retention is 
shorter in men who had a TP biopsy than in those who had a TR biopsy. These 
differences in hospital length of stay suggest that the complications that occur after a 
TP biopsy may be less severe than those after a TR biopsy. 
 
Sepsis remains the most serious complication related to prostate biopsy. However, 
the adjusted risk difference for sepsis requiring subsequent hospital admission 
10 
21st February 2020 – Accepted Manuscript – British Journal of Urology International 
 
between TR and TP biopsy was relatively small. Based on our results, it can be 
estimated that the use of TP rather than TR biopsies would prevent one readmission 
for sepsis in 278 men (= 1 / 0.36%) at the cost of three additional men (= 1.06% / 
0.36%) readmitted for urinary retention. 
 
The higher risk of developing urinary retention requiring hospital readmission 
following a TP biopsy may in part be associated with the use of a general 
anaesthetic and the larger number of cores taken with a TP biopsy. It is important to 
note that there is a gradual shift in clinical practice towards carrying out TP biopsies 
under local anaesthetic and taking fewer but more targeted tissue cores (1, 14, 15). 
It is likely that most of this change in practice has occurred after the study period. 
Such a practice change may help to reduce the subsequent retention and infection 
rate and the need for an overnight stay immediately following TP biopsy. However, 
this hypothesis needs to be tested in further studies. 
 
Another factor which might affect changes in infectious complication risk after 
prostate biopsy and thereby influence the decision to use TP over TR biopsy is the 
decreasing effectiveness of antibiotic prophylaxis (16). These trends suggest that 
over time the trade-off between sepsis and retention risk may become more 
favourable for TP biopsies, given that the higher risk associated with TR biopsies 
(sepsis) may increase and the higher risk associated with TP biopsies (urinary 
retention) is likely to decrease with newer, modified sampling methods. 
 
To address this question, we undertook a sensitivity analysis of our results for each 
year of the inclusion period (2014 -2017) to assess whether the risk of urinary 
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retention and sepsis changed over time. We did not find evidence for a time trend in 
the risk for either complication. For each year the study was undertaken, the 
increased risk of urinary retention observed in the TP group and the increased risk of 
sepsis observed in the TR group remained significant. 
 
Strengths and limitations 
Key strengths of this report, which is part of the National Prostate Cancer Audit, 
include the high number of men studied using data that represent contemporary 
clinical practice, and the relatively high proportion of TP biopsies (18.6%). 
Comorbidity was more prevalent in men who had a TP biopsy. For example, a more 
detailed analysis of specific comorbidities (results not reported) found that the 
prevalence of diabetes, which is an important risk factor for the development of 
complications, was higher in men who had a TP biopsy (11.2%) than in men who 
had a TR biopsy (8.8%) (11). However, all comparisons were adjusted for 
comorbidity. Our findings therefore represent current real-world practice within the 
English NHS, which covers more than 90% of the prostate biopsies carried out in 
England (1, 17). 
 
Our coding framework was developed to identify severe complications that require a 
hospital admission. This method ensured that we only considered complications at a 
specific severity level. However, in doing so we were unable to capture 
complications including minor infections, haematospermia, rectal bleeding and pain, 
most often treated by general practitioners in primary care or in outpatient clinics or 
emergency departments of NHS hospitals. These complications would rarely be 
considered severe enough to require hospital admission. 
12 
21st February 2020 – Accepted Manuscript – British Journal of Urology International 
 
 
A further limitation of our study is that we only included men diagnosed with prostate 
cancer who had a biopsy documented in the HES database. Thus, we were unable 
to report on biopsies carried out in men who had benign changes only. However, we 
do not envisage that biopsy type or the risk of complications would differ between 
men included in the study and those receiving a prostate biopsy but who did not 
subsequently have a confirmed cancer diagnosis. Indication for biopsy was also not 
identified, but the indication for most biopsies is likely to have been the suspicion of 
cancer. 
 
Furthermore, the coding of the type of biopsy may not always be correct. However, a 
systematic review of coding accuracy for urological patients in HES found that about 
90% of the procedure codes were correct (18). Also, coding errors in the type of 
biopsy are unlikely to be associated with biopsy complications which suggests that 
the misclassification is ‘non-differential’. Our results may therefore slightly 
underestimate the true differences in complication rates between men who had a TR 
or a TP biopsy. 
 
We were also unable to determine the differences in the prophylactic antibiotic 
regimens between men who had a TR or TP biopsies. Previous studies have 
reported a potential benefit of TP over TR biopsies, which suggests that prophylactic 
antibiotic regimes are not required routinely.(19) However, the British Association of 
Urological Surgeons advocates the use of prophylactic antibiotics in both TR and TP 
biopsy and in practice prophylaxis is generally used in both groups (20, 21). 
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Finally, we do not have data on prostate size or volume, the number or locations of 
needle insertions, the experience of the practitioner undertaking the biopsies, 
whether a targeted or mapping biopsy method was employed, or whether a local or 
general anaesthetic was used. However, we feel that our comparison is an accurate 
report of the complications after TR and TP biopsies in contemporary practice within 
a publicly funded health system. 
 
Conclusions 
Our results represent real-world practice during a period when the use of TP was 
increasing. TP prostate biopsies are associated with a lower risk of readmission due 
to sepsis compared to TR biopsies. However, this lower risk of sepsis comes at the 
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Figure, Tables and Appendix Legends 
 
Figure 1: Consort Diagram of Patient Selection. 
 
Table 1: Patient characteristics according to prostate biopsy method for men 
diagnosed with prostate cancer between 1st April 2014 and 31st March 2017 in the 
English NHS. 
 
Table 2: Risk of readmission and mean length of hospital stay in the first 30 days 
after transrectal (TR) and transperineal (TP) biopsy. 
 
Appendix: Coding framework based on ICD-10 and OPCS-4 codes 
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Men in the English cancer registry with a 
diagnosis of prostate cancer between 
1st April 2014 – 31st March 2017 
 
n = 118,526 
  
 
Final study group 
 
n = 73,630 
  
 
Transperineal prostate biopsy 
 
n = 13,723 
  
 
Transrectal prostate biopsy 
 
n = 59,907 
 
Men who had a prostate biopsy between 
1st January 2014 – 31st December 2017 
 
n = 75,464 
 
Men excluded from study: 
• Unknown hospital: n = 11 
• Private hospital: n = 1008 
• Unknown biopsy method: n = 815  
  
19 
21st February 2020 – Accepted Manuscript – British Journal of Urology International 
 
Table 1. Patient characteristics according to prostate biopsy method for men diagnosed with 
prostate cancer between 1st April 2014 and 31st March 2017 in the English NHS. 
  
Transrectal biopsy Transperineal biopsy Total  
No. % No. % No. % 
Total 59,907 81.4 13,723 18.6 73,630 100 
 
Biopsy year 
2014 14,744 24.6 2,340 17.1 17,084 23.2 
2015 19,750 33.0 4,334 31.6 24,084 32.7 
2016 19,875 33.2 5,162 37.6 25,037 34.0 
2017 5,538 9.2 1,887 13.8 7,425 10.1 
 
Age group (years) 
< 60 7,941 13.3 2,534 18.5 10,475 14.2 
60-69 22,898 38.2 6,090 44.4 28,988 39.4 
70-79 24,113 40.3 4,676 34.1 28,789 39.1 
≥ 80 4,955 8.3 423 3.1 5,378 7.3 
Comorbidity according to 
RCS Charlson co-morbidity score 
0 46,744 78.0 9,841 71.7 56,585 76.9 
1 9,152 15.3 2,952 21.5 12,104 16.4 
≥2 4,011 6.7 930 6.8 4,941 6.7 
 
Socioeconomic deprivation status 
(quintiles of the national distribution) 
1 (least deprived) 14,169 22.7 4319 25.6 18,488 23.3 
2 14,593 23.4 3874 23.0 18,467 23.3 
3 13,453 21.5 3544 21.0 16,997 21.4 
4 10,976 17.6 2883 17.1 13,859 17.5 
5 (most deprived) 9286 14.9 2230 13.2 11,516 14.5 
 
Ethnicity 
White 52,599 93.6 11,752 90.2 64,351 92.9 
Asian 959 1.7 274 2.1 1,233 1.8 
Black 1,896 3.4 708 5.4 2,604 3.8 
Other 765 1.4 292 2.2 1,057 1.5 
Missing 3,688  697  4,385  
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Table 2 Risk of readmission and mean length of hospital stay in the first 30 days after transrectal 
(TR) and transperineal (TP) biopsy. 
 
Risk of readmission in first 30 days after 
 
 TR TP  
 
number (%) number (%) Adjusted risk  difference* (%) 95% CI P- value 




1,415 (2.36) 1,681 (12.25) 9.70 7.12 to 12.27 <0.001 
Sepsis 806 (1.35) 142 (1.03) -0.36 -0.56 to -0.15 0.001 
Urinary retention  571 (0.95) 265 (1.93) 1.06 0.71 to 1.41 <0.001 
Haematuria 396 (0.66) 97 (0.71) 0.07 -0.15 to 0.28 0.546 
Mortality** 
 59 (0.10) 9 (0.07) -0.03 -0.07 to 0.01 0.197 
 
Length of hospital stay 
 
 TR TP  
  
 Mean (SD) Mean (SD) Adjusted mean 
difference* (%) 95% CI P- value 
      
Number of men  806 142    
Readmission LOS 
(sepsis; days) 6.53 (8.88) 5.08 (3.95) -1.10 -1.84 to -0.36 0.004 
      




3.87 (4.50) 2.58 (2.70) -1.32 -1.97 to -0.66 <0.001 
      
Number of men 396 97    
Readmission LOS 
(haematuria; days) 3.88 (5.78) 3.12 (3.55) -0.70 -2.03 to 0.63 0.304 
 
Abbreviations: LOS = length of hospital stay; RCS = Royal College of Surgeons; 
* Adjusted for biopsy year, age, ethnicity, RCS Charlson score and socioeconomic deprivation status 
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Appendix 1: Coding framework based on ICD-10 and OPCS-4 codes (6) 
 




ICD-10 codes within the first 7 diagnostic fields 
N30.0  Acute cystitis 
N39.0  Urinary tract infection, site not specified 
N41.0  Acute prostatitis 
N41.2 Abscess of prostate 
N41.3 Prostatocystitis 
N41.9 Inflammatory disease of the prostate, unspecified 
N45.0 Orchitis, epididymitis and epididymo-orchitis with abscess 
N45.9 Orchitis, epididymitis and epididymo-orchitis without abscess 
N49 Inflammatory disorder male genital organs 
R36 Urethral discharge 
B96.1 Klebsiella pneumoniae as the cause of diseases classified to other chapters   
B96.2 Escherichia coli as the cause of diseases classified to other chapters 
B96.4 Proteus as the cause of diseases classified to other chapters 
B96.5 Pseudomonas as the cause of diseases classified to other chapters 
B96.8 Other specified bacterial agents as the cause of diseases classified to other chapters 
A41.8 Other specified sepsis 
A41.9 Sepsis, unspecified 
A49.9 Bacterial infection, unspecified 
ICD-10 codes within the first diagnostic field and as part of an emergency admission 
I48 Atrial fibrillation and flutter 




ICD-10 codes within the first 7 diagnostic fields 
R31 Unspecified haematuria 
N42.1 Congestion and haemorrhage of prostate 
OPCS-4 codes within the first 3 procedure fields and as part of an emergency admission 
M45.9 Unspecified diagnostic endoscopic examination of bladder 
M45.8 Other specified diagnostic endoscopic examination of bladder 




ICD-10 codes within the first seven diagnostic fields 
R33  Retention of urine 
ICD-10 codes within the first 2 diagnostic fields and as part of an emergency admission 
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